SG3 Management’s Alexion Pharmaceuticals ALXN Stock Holding History

SG3 Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-120,500	Closed	-$18.8M	–	1583
2020 Q4	$18.8M	Buy	120,500 +24,600	+26%	+$3.16M	0.36%	55
2020 Q3	$11M	Buy	+95,900	New	+$10.3M	0.41%	60
2020 Q1	–	Sell	-5,000	Closed	-$541K	–	487
2019 Q4	$541K	Sell	5,000 -50,000	-91%	-$5.35M	0.03%	140
2019 Q3	$5.39M	Buy	55,000 +30,000	+120%	+$3.38M	0.49%	36
2019 Q2	$3.27M	Buy	+25,000	New	+$3.22M	0.36%	54

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

SG3 Management's ALXN Position: Q3 2021 in Review

SG3 Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 3,000 shares — an estimated $551K sold.

SG3 Management first reported a position in ALXN in Q2 2020 and held it in 4 quarters. The position peaked at $4.73M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

SG3 Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
SG3 Management sold 3,000 Alexion Pharmaceuticals shares in Q3 2021, an estimated $551K.
SG3 Management first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 4 quarters.
SG3 Management's Alexion Pharmaceuticals position peaked at $4.73M in Q4 2020.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on SG3 Management's 13F filing for Q3 2021, filed 15 Nov 2021.